药物基本信息
通用名：埃博拉病毒疫苗
适应症：埃博拉出血热
市场需求
埃博拉出血热是严重的、往往致命的人类疾病，病死率高达90%。它是世界上最凶猛的疾病之一。该疾病通过直接接触受感染的动物或人的血液、体液和组织传播。病情严重的患者需要获得重症支持治疗。疫情期间，与患者或死者有密切接触的卫生工作者、家人以及其他人面临较高的感染风险。 埃博拉出血热疫情可以摧毁家庭和社区，但可以通过在诊所和医院、公共场所或家中采用所推荐的防护措施控制感染。
根据2016年12月23日《柳叶刀》公布的结果，实验性埃博拉疫苗rVSV-ZEBOV，在几内亚的一项重大试验中显示了抵御致命病毒的高度保护性，该疫苗于2015年期间在几内亚11841人中进行了试验研究。这项试验由世界卫生组织、几内亚卫生部和其它一些国际伙伴牵头进行。
The basic information of drug
common name：Ebola virus vaccine
Indications: Treatment of Ebola hemorrhagic fever
Market demand
Ebola hemorrhagic fever is a disease which is serious and often fatal to human with a mortality rate of up to 90%. It is one of the world's most ferocious diseases. The way to spread the infection is to directly contact the infected animal or human blood, body fluids and tissues. Serious patients need severe supportive care. During the outbreak, health workers, family members, and others who are in close contact with the patient or the deceased face a higher risk of infection. The Ebola hemorrhagic fever can destroy families and communities, but it can be controlled by using the recommended protective measures in clinics and hospitals, public places or homes.，
According to the results published on the “Lancet” on December 23, 2016, the experimental Ebola vaccine rVSV-ZEBOV, in a major trial in Guinea, showed a high degree of protection against deadly viruses. During the 2015, the study was conducted in 11841 people in Guinea. The trial was led by the World Health Organization, the Ministry of Health of Guinea and other international partners.
（图片来源中国疾病预防控制中心）
